Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 1 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Endocrine 2CNS 1

Conditions

Pheochromocytoma 2Neuroblastoma 1Endocrine System Diseases 1

Interventions

Specimen Handling 4lutetium Lu 177 dotatate 3gallium Ga 68 dotatate 3Magnetic Resonance Spectroscopy 3olaparib 2cabozantinib 2belzutifan 2Temozolomide 2Nivolumab 2Fluorodeoxyglucose F18 2Biopsy 26-fluorodopamine 23-Iodobenzylguanidine 2tipifarnib 1talazoparib 1spartalizumab 1pembrolizumab 1pegfilgrastim 1lanreotide 1guadecitabine 1fluorodopa F 18 1fludarabine phosphate 1copper dotatate CU-64 1atezolizumab 1Stem Cell Transplantation 1Phenoxybenzamine 1Lutetium-177 1Lutetium 1Ipilimumab 1Interleukin-13 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Pheochromocytoma × 6-fluorodopamine × 1 year × Clear all
NCT00004847 2026-06-03

Diagnosis of Pheochromocytoma

National Institutes of Health Clinical Center (CC)

Phase 1 Recruiting
3,000 enrolled
Endocrine

Endocrine System Diseases, Pheochromocytoma

NCT03541720 2026-04-29

18F-Fluorodopamine PET Studies of Neuroblastoma and Pheochromocytoma

St. Jude Children's Research Hospital

Phase EARLY_PHASE1 Active not recruiting
13 enrolled
CNSEndocrine

Neuroblastoma, Pheochromocytoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡